Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 469
 
About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Advertise Login 
     
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 3  |  Page : 196-201

Melatonin supplementation as an adjuvant therapy in neonatal respiratory distress syndrome


1 Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt
3 Department of Physiology, Faculty of Medicine, Tanta University, Tanta, Egypt
4 Department of Pharmacology and Toxicology, Tanta University, Tanta, Egypt

Correspondence Address:
Dr. Mohamed Shawky Elfarargy
Assistant Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, El-Gharbia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcn.JCN_17_20

Rights and Permissions

Background: Neonatal respiratory distress syndrome (RDS) is a common serious chest disease that is caused by a deficiency of alveolar surfactant. Aim: Detection of the effect of melatonin supplementation in cases of neonatal RDS. Patients and Methods: A prospective randomized clinical trial study which was done at Tanta University Hospital from July 2016 to March 2018 on 100 neonates suffering from respiratory distress which was diagnosed as RDS. The studied neonates were divided into two groups: group 1, which had supplied with melatonin, and group 2, which had not supplied with melatonin. Grades of RDS, down score, malondialdehyde (MDA), superoxide dismutase (SOD), and interleukin-8 (IL-8) were measured on the 1st day and the 5th day of admission in the incubator. The duration of the presence of neonates in the incubator was determined, and the number of cases who needed mechanical ventilation (MV) was calculated. Results: There were significant differences in grades of RDS, Down score, MDA, SOD, IL-8 on the 5th day of admission between Group 1 and 2 (P = 0.001), and between 1st and 5th day of admission in Group 1 (P = 0.001). There was a significant difference between Groups 1 and 2 in the duration of the presence of neonates in the incubator (P = 0.001) and the number of cases who needed MV (P = 0.046). Conclusion: Melatonin supplementation could be used as adjuvant therapy for the treatment of RDS in neonates, but further studies involving a larger number of neonates must be performed on this topic. Recommendation: Melatonin supplementation for RDS neonates.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
  Search Pubmed for
  Search in Google Scholar for
Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed139    
    Printed6    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal